TrialBone marrow transplantation2022

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

Richard LeBlanc et al.PubMed ↗Publisher ↗

No numbers read from the abstract.